🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

14+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 14 recruiting trials for “hepatosplenic-t-cell-lymphoma”

Phase 1RecruitingNCT07388563 ↗

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

👨‍⚕️ Max J Gordon, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2026View details ↗
Phase 2RecruitingNCT07159620 ↗

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

🏥 The First Affiliated Hospital of Soochow University📍 1 site📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT07168317 ↗

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

👨‍⚕️ Wei Sang Doctor📍 1 site📅 Started Aug 2025View details ↗
Phase 1RecruitingNCT07108868 ↗

A Phase I Dose Finding Study of MB-CART2219.1

🏥 University Hospital Tuebingen📍 2 sites📅 Started Jun 2025View details ↗
Phase 3RecruitingNCT06522737 ↗

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

🏥 SecuraBio📍 43 sites📅 Started May 2025View details ↗
Phase 2RecruitingNCT07058103 ↗

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

🏥 The Affiliated Hospital of Xuzhou Medical University📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06756308 ↗

A Study of Enasidenib in People With T-Cell Lymphoma

👨‍⚕️ Zachary Epstein-Peterson, MD, Memorial Sloan Kettering Cancer Center📍 8 sites📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06698003 ↗

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

👨‍⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Nov 2024View details ↗
Phase 1RecruitingNCT06393738 ↗

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

🏥 Arvinas Inc.📍 17 sites📅 Started Sep 2024View details ↗
Phase 1, PHASE2RecruitingNCT06420076 ↗

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

🏥 Essen Biotech📍 1 site📅 Started Jul 2024View details ↗
Phase 1, PHASE2RecruitingNCT07075328 ↗

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

🏥 Otsuka Medical Devices Co., Ltd. Japan📍 4 sites📅 Started Apr 2024View details ↗
RecruitingNCT06131801 ↗

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

👨‍⚕️ Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati📍 5 sites📅 Started Nov 2023View details ↗
RecruitingNCT05978141 ↗

A Registry for People With T-cell Lymphoma

👨‍⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 26 sites📅 Started Jul 2023View details ↗
Phase 1RecruitingNCT04848064 ↗

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

👨‍⚕️ John C Reneau, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started May 2022View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →